Centiva Capital’s Enzo Biochem, Inc. ENZ Stock Holding History

Centiva Capital’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-19,610	Closed	-$36.1K	–	2179
2023 Q2	$36.1K	Buy	+19,610	New	+$45.4K	﹤0.01%	1519

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Centiva Capital's ENZ Position: Q3 2023 in Review

Centiva Capital sold out of Enzo Biochem, Inc. (ENZ) in Q3 2023, closing a stake of 19,610 shares — an estimated $36.1K sold.

Centiva Capital first reported a position in ENZ in Q2 2023 and held it in 1 quarter. The position peaked at $36.1K in Q2 2023. 39 funds tracked by Wall St. Rank hold ENZ as of Q3 2023.

Centiva Capital reported no remaining Enzo Biochem, Inc. position as of Q3 2023 after selling out during the quarter.
Centiva Capital sold 19,610 Enzo Biochem, Inc. shares in Q3 2023, an estimated $36.1K.
Centiva Capital first reported a position in Enzo Biochem, Inc. in Q2 2023 and held it in 1 quarter.
Centiva Capital's Enzo Biochem, Inc. position peaked at $36.1K in Q2 2023.
39 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.